Concepts of lines of therapy in cancer treatment: findings from an expert interview-based study.
Expert interview
Lines of therapy
Therapy planning
cancer treatment
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
received:
28
07
2023
accepted:
25
04
2024
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
15
5
2024
Statut:
epublish
Résumé
The concept of lines of therapy (LOT) in cancer treatment is often considered for decision making in tumor boards and clinical management, but lacks a common definition across medical specialties. The complexity and heterogeneity of malignancies and treatment modalities contribute to an inconsistent understanding of LOT among physicians. This study assesses the heterogeneity of understandings of the LOT concept, its major dimensions, and criteria from the perspective of physicians of different specialties with an oncological focus in Germany. Semi-structured expert interviews with nine physicians were conducted and evaluated using qualitative content analysis. Most interviewees agreed that there is no single definition for LOT and found it difficult to explicate their understanding. A majority of experts stated that they had already encountered misunderstandings with colleagues regarding LOT and that they had problems with deciphering LOT from the medical records of their patients. Disagreement emerged about the roles of the following within the LOT concept: maintenance therapy, treatment intention, different therapy modalities, changing pharmaceutical agents, and therapy breaks. Respondents predominantly considered the same criteria as decisive for the definition of LOT as for a change in LOT (e.g., the occurrence of a progression event or tumor recurrence).
Identifiants
pubmed: 38750530
doi: 10.1186/s13104-024-06789-6
pii: 10.1186/s13104-024-06789-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Informations de copyright
© 2024. The Author(s).
Références
Saini KS, Twelves C. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br J Canc. 2021;125(2):155–63.
doi: 10.1038/s41416-021-01319-8
OPTUM. Determining lines of therapy (LOT) in oncology in claims databases. 2018. https://www.optum.com/content/dam/optum3/optum/en/resources/white-papers/guidelines-for-determining-lines-of-therapy-whitepaper.pdf . Accessed 28 March 2023.
Hess LM, Li X, Wu Y, Goodloe RJ, Cui ZL. Defining treatment regimens and lines of therapy using real-world data in oncology. Future Oncol. 2021;17(15):1865–77.
doi: 10.2217/fon-2020-1041
pubmed: 33629590
Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126(7):921–2.
doi: 10.1182/blood-2015-05-647636
pubmed: 26272048
Carroll NM, Burniece KM, Holzman J, McQuillan DB, Plata A, Ritzwoller DP. Algorithm to identify systemic cancer therapy treatment using structured electronic data. JCO Clin Cancer Inf. 2017;1:1–9.
Weymann D, Costa S, Regier DA. Validation of a cyclic algorithm to proxy number of lines of systemic cancer therapy using administrative data. JCO Clin Cancer Inf. 2019;3:1–10.
Döringer S. The problem-centred expert interview’. Combining qualitative interviewing approaches for investigating implicit expert knowledge. Int J Soc Res Methodol. 2021;24(3):265–78.
doi: 10.1080/13645579.2020.1766777
Cooke NM, McDonald JE. A formal methodology for acquiring and representing expert knowledge. Proc IEEE Inst Electr Electron Eng. 1986;74(10):1422–30.
doi: 10.1109/PROC.1986.13643
Kallio H, Pietilä AM, Johnson M, Kangasniemi M. Systematic methodological review: developing a framework for a qualitative semi-structured interview guide. J Adv Nurs. 2016;72(12):2954–65.
doi: 10.1111/jan.13031
pubmed: 27221824
Mayring P. Qualitative content analysis: demarcation, varieties, developments. Forum Qual Social Res. 2019;20(3):1–26.
Abrams T, Hess LM, Zhu YE, Schelman W, Liepa AM, Fuchs C. Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the US. Gastric Cancer. 2018;21:738–44.
doi: 10.1007/s10120-018-0802-5
pubmed: 29392573
Meng W, Ou W, Chandwani S, Chen X, Black W, Cai Z. Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer. J Biomed Inf. 2019;100:103335.
doi: 10.1016/j.jbi.2019.103335
Shah S, Raskin L, Cohan D, Freeman M, Hamid O. Treatment patterns of malignant melanoma in the United States from 2011 to 2016: a retrospective cohort study. CMRO. 2020;36:63–72.
Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 2010;6(6):301–7.
doi: 10.1200/JOP.2010.000072
pubmed: 21358960
pmcid: 2988664
Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, Lam A, Ukropec J, Maiese EM, Nair S, Potluri R, Voorhees PM. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20:1087.
doi: 10.1186/s12885-020-07503-y
pubmed: 33172403
pmcid: 7656738
Cho J, Lee EH. Reducing confusion about grounded theory and qualitative content analysis: similarities and differences. Qual Rep. 2014;19(64):1–20.